- $3.23m
- -$0.33m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.47 | ||
| Price to Tang. Book | 2.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -950.6% | ||
| Return on Equity | -233.69% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. It has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 16th, 2019
- Public Since
- January 12th, 2022
- No. of Shareholders
- 39
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 2,209,910
- Address
- 1200 Route 22 East, BRIDGEWATER, 08807
- Web
- https://tharimmune.com/
- Phone
- +1 3027432995
- Auditors
- ROSENBERG RICH BAKER BERMAN, P.A.
Upcoming Events for THAR
Similar to THAR
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Tharimmune share price?
As of Today at 23:40 UTC, shares in Tharimmune are trading at $1.53. This share price information is delayed by 15 minutes.
How has the Tharimmune share price performed this year?
Shares in Tharimmune last closed at $1.53 and the price had moved by -72.98% over the past 365 days. In terms of relative price strength the Tharimmune share price has underperformed the S&P500 Index by -75.63% over the past year.
What are the analyst and broker recommendations for Tharimmune?
The overall consensus recommendation for Tharimmune is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Tharimmune dividend yield?
Tharimmune does not currently pay a dividend.
Does Tharimmune pay a dividend?
Tharimmune does not currently pay a dividend.
When does Tharimmune next pay dividends?
Tharimmune does not currently pay a dividend.
How do I buy Tharimmune shares?
To buy shares in Tharimmune you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tharimmune?
As of the previous close price of $1.53, shares in Tharimmune had a market capitalisation of $3.23m.
Where are Tharimmune shares listed?
Here are the trading details for Tharimmune:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: THAR
What kind of share is Tharimmune?
Based on an overall assessment of its quality, value and momentum Tharimmune is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tharimmune share price forecast for 2025?
The analyst consensus target price for shares in Tharimmune is $5.00. That is 226.78% above the last closing price of $1.53.
Analysts covering Tharimmune currently have a consensus Earnings Per Share (EPS) forecast of -$7.06 for the next financial year.
Find out moreWhat is the trend in the Tharimmune share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tharimmune. Over the past six months, its share price has underperformed the S&P500 Index by -42.86%.
As of the last closing price of $1.53, shares in Tharimmune were trading -29.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tharimmune PE Ratio?
The Tharimmune PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tharimmune?
We do not have data on Tharimmune's directors